Imricor Medical Systems (IMR) H1 2024 earnings summary

Executive summary

• Achieved record balance sheet strength through successful capital raises and regulatory milestones, including Saudi FDA and CE Mark approvals for the Vision-MR Diagnostic Catheter under new EU regulations.

• Expanded global presence with new hospital installations and first iCMR-guided procedures in Croatia, Hungary, Switzerland, and the U.S., including Johns Hopkins.

• World's first and only MRI-compatible platform for cardiac ablations, targeting improved outcomes and lower costs.

• Two pivotal global trials in 2024 (Europe and US) to expand indications and market access, with U.S. FDA trial (VISABL-AFL) progressing and preparation for the first MRI-guided VT ablation trial.

• Well-funded balance sheet to support upcoming milestones, but substantial doubt remains about going concern due to recurring losses and negative cash flows.

Financial highlights

• Total revenue for H1 2024 was $408,000, up 105% year-over-year, mainly from equipment and product sales.

• Consumable product sales were $154,000, flat year-over-year, but Q2 saw a 350% sequential increase over Q1.

• Net loss for the period was $6.86 million, a 25.6% improvement year-over-year, primarily due to fair value changes in convertible notes and derivatives.

• Operating cash outflow was $8 million, up $1.8 million year-over-year, mainly due to lower accounts payable.

• Cash at June 30, 2024 was $1.5 million, with a pro forma post-raise balance of $24.8 million if both capital tranches are approved.

Outlook and guidance

• On track to complete the U.S. FDA trial and targeting FDA approval by mid-2025, with U.S. launch targeted for 2025.

• Preparing for the first MRI-guided VT ablation in early Q4, with expected acceleration in hospital adoption and revenue.

• VT trial in Europe expected to complete Q3 2025, with CE Mark approval mid-2026.

• Actively recruiting sales staff and expanding geographically to support anticipated demand growth post-VT trial.

• Substantial doubt remains about going concern, but management plans to raise additional working capital if needed.